A new analysis has been launched by the US Centers for Medicare and Medicaid Services (CMS) to evaluate the nationwide coverage of HIV preexposure prophylaxis (PrEP), a group of antiretroviral drugs that prevent HIV infections and transmission when taken appropriately. The drugs, which hover at around $2300 a year, fall under Medicare coverage for some states but not all.
A US federal judge has ruled that an ACA provision guaranteeing HIV pre-exposure prophylaxis (PrEP) is unconstitutional, in a suit filed by Braidwood Management. PrEP is a medication that, if taken correctly, effectively prevents HIV infections and transmission. Requiring Braidwood to cover the drug would, according to the ruling, violate their religious freedoms.